Implantica AG (IPLTF)
| Market Cap | 469.84M +17.1% |
| Revenue (ttm) | 2.82M +25.7% |
| Net Income | -22.53M |
| EPS | -0.08 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 6.30 |
| Previous Close | 7.45 |
| Day's Range | 6.30 - 6.30 |
| 52-Week Range | 4.66 - 7.45 |
| Beta | 0.61 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 19, 2026 |
About Implantica AG
Implantica AG engages in the research and distribution of medical implants in Switzerland and Spain. The company’s lead product candidate is RefluxStop, a passive CE-marked implant for prevention of gastroesophageal reflux disease. It focuses on two treatment areas, Gastrointestinal surgery and Urology. It is also involved in the development of eHealth platform, a digital health system monitor, transmit, and actively treat conditions from within the body; e-InVivo, a sensor implants to monitor a multitude of health parameters and provide diagno... [Read more]
Financial Performance
In 2025, Implantica AG's revenue was 2.07 million, an increase of 7.08% compared to the previous year's 1.94 million. Losses were -19.63 million, -15.89% less than in 2024.
Financial numbers in EUR Financial StatementsNews
Implantica announces leading U.S. surgeon participates in RefluxStop® training surgeries
VADUZ, Liechtenstein, Oct. 27, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, today announced that Dr. John C.
Implantica's Capital Markets Day webcast available on demand
VADUZ, Liechtenstein, Sept. 11, 2026 /PRNewswire/ -- Implantica AG (publ.) would like to thank all who attended its Capital Markets Day in Stockholm on September 9, 2026.